Zealand Pharma wants to be world-leading within five years

Within the next half decade, Zealand Pharma aims to be one of the world leaders in treatment of rare metabolic disorders and gastrointestinal diseases. The foundation for success will be laid this year with four late-phase programs and an upcoming launch of two self-owned drugs.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Lundbeck på FDA's sorte liste: Vi forstår det ikke

De amerikanske sundhedsmyndigheder har offentliggjort en liste med selskaber, der kan have benyttet sig af tvivlsomme taktikker for at forsinke generisk konkurrence. Lundbeck er blandt dem, men det er helt forfejlet, siger selskabets pressechef.

Related articles